Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
About Compass Therapeutics Inc.
Compass Therapeutics Inc. (Nasdaq: CMPX) is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing innovative antibody-based therapeutics to treat a range of cancers and other human diseases. Headquartered in Boston, Massachusetts, Compass leverages cutting-edge science to address the intricate relationship between angiogenesis, the immune system, and tumor growth. The company’s mission is to deliver transformative therapies that target critical biological pathways, enabling more effective anti-tumor responses.
Core Focus and Proprietary Platforms
Compass Therapeutics is at the forefront of antibody discovery and development, with a focus on bispecific antibodies, monoclonal antibodies, and engineered protein constructs. The company’s proprietary platforms, including StitchMabs and common light chain technologies, empower researchers to empirically identify optimal drug combinations. This approach allows for rapid translation of preclinical insights into tailored therapeutics with monoclonal-like manufacturability, positioning Compass as a leader in the field of combinatorial immunotherapy.
Pipeline and Clinical Programs
Compass Therapeutics boasts a robust pipeline targeting multiple critical pathways involved in tumor progression and immune evasion:
- Tovecimig (CTX-009): A bispecific antibody targeting DLL4 and VEGF-A, designed to inhibit angiogenesis and tumor vascularization. Currently in Phase 2/3 clinical trials for advanced biliary tract cancers (BTC) and being evaluated for additional indications like colorectal cancer (CRC).
- CTX-471: A novel CD137 agonist antibody that activates immune effector cells within the tumor microenvironment. Early clinical results suggest potential efficacy in melanoma, small-cell lung cancer, and mesothelioma, with biomarker-driven Phase 2 trials planned.
- CTX-8371: A next-generation bispecific checkpoint inhibitor targeting PD-1 and PD-L1, with a unique mechanism involving proteolytic cleavage of cell surface PD-1. This program is in Phase 1 trials for solid tumors.
- CTX-10726: A newly announced PD-1 x VEGF-A bispecific antibody advancing through preclinical development, with an IND submission expected by year-end 2025.
These candidates reflect Compass’s commitment to addressing high unmet medical needs, particularly in patient populations resistant to existing therapies.
Scientific Excellence and Biomarker-Driven Strategy
Compass Therapeutics integrates biomarker-driven strategies into its clinical development programs. For example, the identification of NCAM (CD56) as a potential biomarker for CTX-471 highlights the company’s ability to leverage cutting-edge science to enhance patient selection and therapeutic efficacy. Similarly, the use of DLL4 as a biomarker in CRC studies underscores Compass’s precision medicine approach.
Collaborative and Industrialized Approach
The company’s “partnership-first” mentality enables it to collaborate with top-tier academic institutions and leverage best-in-class technologies. This decentralized validation model accelerates the transition from discovery to clinical development, ensuring that only the most promising therapeutic combinations advance to human trials.
Competitive Landscape and Market Position
Operating in the highly competitive field of oncology-focused biopharmaceuticals, Compass Therapeutics distinguishes itself through its emphasis on bispecific antibodies and its robust biomarker-driven approach. Competitors include established players like Genentech and Bristol Myers Squibb, but Compass’s focus on immune-oncology and angiogenesis modulation positions it uniquely within the market. The company’s ability to identify and exploit novel biological pathways gives it a competitive edge in addressing complex cancer mechanisms.
Challenges and Opportunities
While Compass Therapeutics faces challenges typical of clinical-stage biopharma companies—such as regulatory hurdles and the inherent risks of drug development—it is well-positioned to overcome these obstacles through its innovative platforms, strong clinical pipeline, and strategic collaborations. The growing emphasis on immuno-oncology and biomarker-driven therapies provides significant opportunities for the company to expand its impact and market presence.
Conclusion
Compass Therapeutics Inc. exemplifies innovation and scientific rigor in the biopharmaceutical industry. With a robust pipeline, proprietary technologies, and a focus on addressing unmet medical needs, the company is poised to make significant contributions to the field of oncology. By targeting critical pathways involved in tumor growth and immune modulation, Compass is advancing the next generation of cancer therapeutics, offering hope to patients worldwide.
Compass Therapeutics (NASDAQ: CMPX) announced significant results from its Phase 2/3 COMPANION-002 trial evaluating tovecimig in combination with paclitaxel for biliary tract cancer (BTC). The study met its primary endpoint, demonstrating a 17.1% overall response rate (ORR) for the combination therapy compared to 5.3% for paclitaxel alone (p=0.031).
The trial enrolled 168 patients with advanced BTC in the second-line setting, randomized 2:1 to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). Notable findings include one complete response in the combination arm and lower progressive disease rates (16.2% vs 42.1%). Secondary endpoints, including progression-free survival and overall survival, are expected to be reported in Q4 2025.
This development is particularly significant as approximately 23,000 BTC patients are diagnosed annually in the US, with 85% lacking approved second-line treatment options.
Compass Therapeutics (Nasdaq: CMPX) has announced a webcast scheduled for April 1, 2025, at 8:00 AM ET to present top-line clinical data from their ongoing Phase 2/3 COMPANION-002 trial. The study evaluates tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel for treating patients with advanced biliary tract cancer (BTC).
The virtual event will be accessible via webcast, with a replay available for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX) reported its 2024 financial results and provided key pipeline updates. The company's lead candidate tovecimig is on track for Phase 2/3 top-line data readout in biliary tract cancer by Q1 2025. The company ended 2024 with $127 million in cash, providing runway into Q1 2027.
Financial highlights include a net loss of $49.4 million ($0.36 per share) compared to $42.5 million in 2023. R&D expenses increased 11% to $42.3 million, while G&A expenses rose 24% to $15.1 million.
Pipeline progress includes:
- Advancement of CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards IND filing by end-2025
- Full enrollment of third dosing cohort for CTX-8371 Phase 1 study
- Planned initiation of two Phase 2 trials in mid-2025 for tovecimig and CTX-471
- 5% ORR achieved for tovecimig in colorectal cancer patients
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.
The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.
Compass Therapeutics (NASDAQ: CMPX) provided a corporate update highlighting key developments in its oncology pipeline. The company's lead candidate tovecimig (CTX-009) is on track for Phase 2/3 top-line data in biliary tract cancer by Q1 2025. A new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, is advancing with IND submission expected by end of 2025.
Two Phase 2 biomarker trials are planned for mid-2025: tovecimig in DLL4-positive colorectal cancer and CTX-471 in NCAM/CD56 expressing tumors. The Phase 1 dose-escalation study of CTX-8371 has fully enrolled its third cohort, with preliminary data expected in H2 2025.
The company reports an estimated $127 million in cash and marketable securities at YE 2024, providing runway into Q1 2027.
Compass Therapeutics (CMPX) has appointed Barry Shin as Chief Financial Officer effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical leadership, including finance, operations, investment banking, and corporate advisory roles. Most recently, he served as EVP, COO & CFO at Trevena, Inc.
The appointment comes at a important time for Compass, with several key catalysts expected in 2025, including topline data readout for CTX-009 in the first quarter. CEO Thomas Schuetz highlighted Shin's expertise in financial planning, capital markets, and M&A as valuable assets for advancing CTX-009 and the company's portfolio of clinical and pre-clinical assets.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. The company's presentation is scheduled for Wednesday, December 4, 2024, from 9:50-10:10 AM EST. A webcast of the presentation will be available and archived for 90 days on Compass' Events page.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 PM ET, and at the Jefferies London Healthcare Conference in London on November 21 at 2:00 PM GMT. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX) reported Q3 2024 financial results and corporate updates. The company fully enrolled its Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected by Q1 2025. Net loss was $10.5 million ($0.08 per share) for Q3 2024. The company maintains a strong financial position with $135 million in cash and marketable securities, providing runway into Q1 2027. R&D expenses were $8.6 million, while G&A expenses increased to $3.6 million. Key pipeline developments include progress in CTX-471 trials with NCAM identified as a potential response biomarker, and advancement in CTX-8371's Phase 1 dose-escalation study.
Compass Therapeutics presented new biomarker data for CTX-471, their novel anti-CD137 agonist antibody, at the SITC Annual Meeting. The study revealed a significant correlation between neural cell adhesion molecule (NCAM/CD56) expression and patient response to CTX-471 monotherapy. The data comes from a Phase 1 trial in patients with advanced malignancies who previously progressed on PD-1/PD-L1 inhibitors. Key findings showed that tumor cell NCAM appears to enrich activated NK cells in the tumor microenvironment, suggesting NCAM's potential use as a selection marker for future clinical trials.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics Inc. specialize in?
What are Compass Therapeutics’ key pipeline products?
How does Compass Therapeutics differentiate itself in the oncology market?
What is the significance of biomarkers in Compass’s clinical programs?
What challenges does Compass Therapeutics face?
What is the company’s approach to collaboration?
What are the clinical applications of Tovecimig (CTX-009)?
What is CTX-471, and how does it work?
